MG53 is identified as a primary determinant of cardiac ischemic preconditioning, highlighting it as a potential therapeutic target for ischemic heart disease.
These results establish MG53 as a primary component of the cardiac IPC response, thus identifying a potentially important novel therapeutic target for the treatment of ischemic heart disease.
Cao et al. (Tue,) studied this question.